Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Oric Pharmaceuticals stock

ORIC
US68622P1093
A2P208

Price

8.29
Today +/-
+0.22
Today %
+2.75 %

Oric Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Oric Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Oric Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Oric Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Oric Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Oric Pharmaceuticals Stock Price History

DateOric Pharmaceuticals Price
1/2/20258.29 undefined
12/31/20248.07 undefined
12/30/20248.17 undefined
12/27/20248.25 undefined
12/26/20248.35 undefined
12/24/20248.19 undefined
12/23/20248.33 undefined
12/20/20248.21 undefined
12/19/20247.69 undefined
12/18/20247.68 undefined
12/17/20248.25 undefined
12/16/20248.24 undefined
12/13/20248.52 undefined
12/12/20248.43 undefined
12/11/20248.96 undefined
12/10/20249.02 undefined
12/9/20249.49 undefined
12/6/20249.90 undefined
12/5/20249.56 undefined
12/4/20249.80 undefined

Oric Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oric Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oric Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oric Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oric Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oric Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oric Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oric Pharmaceuticals’s growth potential.

Oric Pharmaceuticals Revenue, EBIT and net profit per share

DateOric Pharmaceuticals RevenueOric Pharmaceuticals EBITOric Pharmaceuticals Net Income
2029e353.27 M undefined45.62 M undefined57.1 M undefined
2028e173.27 M undefined-134.81 M undefined-50.39 M undefined
2027e40.9 M undefined-201.54 M undefined-146.12 M undefined
2026e12.01 M undefined-192.31 M undefined-144.67 M undefined
2025e0 undefined-172.22 M undefined-147.63 M undefined
2024e0 undefined-144.06 M undefined-131.81 M undefined
20230 undefined-110.78 M undefined-100.7 M undefined
20220 undefined-91.77 M undefined-89.12 M undefined
20210 undefined-78.87 M undefined-78.72 M undefined
20200 undefined-49.35 M undefined-73.7 M undefined
20190 undefined-28.57 M undefined-26.88 M undefined
20180 undefined-22.37 M undefined-21.36 M undefined

Oric Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
000000001240173353
---------233.33332.50104.05
------------
000000000000
-21-26-73-78-89-100-131-147-144-146-5057
-23.81180.776.8514.1012.3631.0012.21-2.041.39-65.75-214.00
27.5427.5421.9437.9539.6651.45000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Oric Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Oric Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
42.689.2293.6237206.3208.19
000000
000000
000000
1.10.83.13.54.24.41
43.790296.7240.5210.5212.6
2.52.222.43.32.86
00043.42226.85
000000
000000
000000
0.51.90.312.311.59.7
34.12.358.136.839.41
46.794.1299298.6247.3252.01
           
107.3178.10000.01
1.42.6456.2518.2557.9658.75
-65.8-92.7-166.4-245.2-335.5-434.67
000000
000000
42.988289.8273222.4224.09
0.40.20.81.91.30.94
1.64.77.713.314.119.51
600500500000
000000
000000
2.65.4915.215.420.46
000000
000000
1.30.80.210.59.47.46
1.30.80.210.59.47.46
3.96.29.225.724.827.92
46.894.2299298.7247.2252.01
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Oric Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Oric Pharmaceuticals's financial health and stability.

Assets

Oric Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Oric Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Oric Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Oric Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-21-26-73-78-89-100
01,0000001,000
000000
012404
0230272724
000000
000000
-20-23-45-59-75-85
0000-20
00-215158-109-43
00-215159-107-42
000000
000000
3870271502585
3870250492585
---21.00-1.00--
000000
1646-10148-159-43
-21.21-24.3-45.94-60.48-77.22-86.54
000000

Oric Pharmaceuticals stock margins

The Oric Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oric Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oric Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oric Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Oric Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oric Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oric Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oric Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oric Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oric Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oric Pharmaceuticals Margin History

Oric Pharmaceuticals Gross marginOric Pharmaceuticals Profit marginOric Pharmaceuticals EBIT marginOric Pharmaceuticals Profit margin
2029e0 %12.91 %16.16 %
2028e0 %-77.8 %-29.08 %
2027e0 %-492.74 %-357.26 %
2026e0 %-1,601.52 %-1,204.82 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %

Oric Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Oric Pharmaceuticals earnings per share therefore indicates how much revenue Oric Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oric Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oric Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oric Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oric Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Oric Pharmaceuticals Revenue, EBIT and net profit per share

DateOric Pharmaceuticals Sales per ShareOric Pharmaceuticals EBIT per shareOric Pharmaceuticals Earnings per Share
2029e5.01 undefined0 undefined0.81 undefined
2028e2.46 undefined0 undefined-0.71 undefined
2027e0.58 undefined0 undefined-2.07 undefined
2026e0.17 undefined0 undefined-2.05 undefined
2025e0 undefined0 undefined-2.09 undefined
2024e0 undefined0 undefined-1.87 undefined
20230 undefined-2.15 undefined-1.96 undefined
20220 undefined-2.31 undefined-2.25 undefined
20210 undefined-2.08 undefined-2.07 undefined
20200 undefined-2.25 undefined-3.36 undefined
20190 undefined-1.04 undefined-0.98 undefined
20180 undefined-0.81 undefined-0.78 undefined

Oric Pharmaceuticals business model

Oric Pharmaceuticals Inc. is a biotechnology company focused on the discovery and development of novel therapeutic approaches for cancer. The company was founded in 2014 by an experienced management team and reputable investors with extensive knowledge in the development and commercialization of cancer drugs. The company is headquartered in Durham, North Carolina, USA. Oric Pharmaceuticals operates a unique business model that focuses on the development of drugs that specifically target cancer cells, thereby increasing therapeutic effectiveness and reducing side effects. The company utilizes a combination of advanced technologies such as genomics, proteomics, and artificial intelligence to develop novel compounds and treatment approaches. The company conducts its research in two business areas: 1) Refinement of the Oric-006 program: The Oric-006 program is a focus of Oric Pharmaceuticals, involving a novel approach to combating cancer. The company has discovered that the protein kinase inhibitor, or Oric-006, is capable of killing tumor cells in patients with advanced tumors. Additionally, the medication is able to slow the spread and inhibit the growth of cancer cells. The company is researching the refinement of Oric-006 and is currently in phase 1b/2 clinical trials. 2) Development of additional compounds: Oric Pharmaceuticals focuses on the development of further therapeutic approaches that can be specifically utilized against specific types of cancer. The company is working on various technologies and platforms to develop new compounds and test their effects against cancer cells. Oric Pharmaceuticals' products have the potential to positively impact the lives of cancer patients and reduce the need for chemotherapy and radiation therapy. The company recognizes the necessity for personalized medicine and utilizes it in the identification of new therapeutic approaches. The company plans to bring its products to market through partnerships and targeted marketing. Oric Pharmaceuticals collaborates closely with experts and leading research institutions for the marketing of their products. Overall, Oric Pharmaceuticals is an innovative company that could play a leading role in the industry due to its focus on personalized cancer medicine and the utilization of cutting-edge technologies. With an experienced management team and reputable investors, the company is positioned for further growth in the future. Oric Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Oric Pharmaceuticals SWOT Analysis

Strengths

Oric Pharmaceuticals Inc has several internal strengths that contribute to its success:

  • Strong and experienced leadership team.
  • Innovative and proprietary drug development technologies.
  • Extensive portfolio of intellectual property rights.
  • Robust financial position and access to capital.
  • Established partnerships with leading research institutions.

Oric Pharmaceuticals Inc faces certain internal weaknesses:

  • Limited market presence and brand recognition.
  • Relatively small size compared to industry giants.
  • Dependency on a single drug or technology platform.
  • Lack of diversification in product pipeline.
  • High research and development costs.

Oric Pharmaceuticals Inc can leverage the following external opportunities:

  • Increasing demand for targeted cancer therapies.
  • Collaboration opportunities with pharmaceutical companies.
  • Expanding global pharmaceutical market.
  • Government initiatives supporting drug development and research.
  • Rising investments in precision medicine and genomics.

Oric Pharmaceuticals Inc faces the following external threats:

  • Intense competition from larger pharmaceutical companies.
  • Regulatory hurdles in drug approval processes.
  • Pricing pressures and reimbursement challenges.
  • Uncertainty in healthcare policies and regulations.
  • Rapidly evolving technological landscape.

Weaknesses

Oric Pharmaceuticals Inc faces certain internal weaknesses:

  • Limited market presence and brand recognition.
  • Relatively small size compared to industry giants.
  • Dependency on a single drug or technology platform.
  • Lack of diversification in product pipeline.
  • High research and development costs.

Oric Pharmaceuticals Inc can leverage the following external opportunities:

  • Increasing demand for targeted cancer therapies.
  • Collaboration opportunities with pharmaceutical companies.
  • Expanding global pharmaceutical market.
  • Government initiatives supporting drug development and research.
  • Rising investments in precision medicine and genomics.

Oric Pharmaceuticals Inc faces the following external threats:

  • Intense competition from larger pharmaceutical companies.
  • Regulatory hurdles in drug approval processes.
  • Pricing pressures and reimbursement challenges.
  • Uncertainty in healthcare policies and regulations.
  • Rapidly evolving technological landscape.

Opportunities

Oric Pharmaceuticals Inc can leverage the following external opportunities:

  • Increasing demand for targeted cancer therapies.
  • Collaboration opportunities with pharmaceutical companies.
  • Expanding global pharmaceutical market.
  • Government initiatives supporting drug development and research.
  • Rising investments in precision medicine and genomics.

Oric Pharmaceuticals Inc faces the following external threats:

  • Intense competition from larger pharmaceutical companies.
  • Regulatory hurdles in drug approval processes.
  • Pricing pressures and reimbursement challenges.
  • Uncertainty in healthcare policies and regulations.
  • Rapidly evolving technological landscape.

Threats

Oric Pharmaceuticals Inc faces the following external threats:

  • Intense competition from larger pharmaceutical companies.
  • Regulatory hurdles in drug approval processes.
  • Pricing pressures and reimbursement challenges.
  • Uncertainty in healthcare policies and regulations.
  • Rapidly evolving technological landscape.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Oric Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Oric Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Oric Pharmaceuticals shares outstanding

The number of shares was Oric Pharmaceuticals in 2024 — This indicates how many shares 51.451 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oric Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oric Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oric Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oric Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Oric Pharmaceuticals.

Oric Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.49 -0.49  (-0.41 %)2024 Q3
6/30/2024-0.42 -0.45  (-7.04 %)2024 Q2
3/31/2024-0.44 -0.37  (16.82 %)2024 Q1
12/31/2023-0.5 -0.49  (1.25 %)2023 Q4
9/30/2023-0.47 -0.44  (6.6 %)2023 Q3
6/30/2023-0.58 -0.5  (13.87 %)2023 Q2
3/31/2023-0.55 -0.53  (3.81 %)2023 Q1
12/31/2022-0.55 -0.52  (4.95 %)2022 Q4
9/30/2022-0.56 -0.63  (-11.6 %)2022 Q3
6/30/2022-0.61 -0.51  (16.68 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the Oric Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

40/ 100

🌱 Environment

36

👫 Social

63

🏛️ Governance

20

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Oric Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
7.61846 % Pfizer Inc5,376,34403/31/2024
7.49003 % Nextech Invest, Ltd.5,285,71406/30/2024
6.97139 % Fidelity Management & Research Company LLC4,919,713-104,2406/30/2024
6.22719 % VR Adviser, LLC4,394,52706/30/2024
5.87056 % Frazier Life Sciences Management, L.P.4,142,85506/30/2024
5.80051 % BlackRock Institutional Trust Company, N.A.4,093,4201,200,1476/30/2024
5.66813 % Viking Global Investors LP4,000,00006/30/2024
5.01740 % The Column Group LP3,540,77706/30/2024
4.84351 % EcoR1 Capital, LLC3,418,06806/30/2024
4.52038 % The Vanguard Group, Inc.3,190,034307,9796/30/2024
1
2
3
4
5
...
10

Oric Pharmaceuticals Executives and Management Board

Dr. Jacob Chacko

(44)
Oric Pharmaceuticals President, Chief Executive Officer, Director (since 2018)
Compensation 4.37 M

Mr. Dominic Piscitelli

(49)
Oric Pharmaceuticals Chief Financial Officer
Compensation 1.92 M

Dr. Pratik Multani

(56)
Oric Pharmaceuticals Chief Medical Officer
Compensation 1.91 M

Dr. Richard Heyman

(65)
Oric Pharmaceuticals Independent Chairman of the Board (since 2015)
Compensation 239,868

Ms. Mardi Dier

(59)
Oric Pharmaceuticals Independent Director
Compensation 200,868
1
2

Most common questions regarding Oric Pharmaceuticals

What values and corporate philosophy does Oric Pharmaceuticals represent?

Oric Pharmaceuticals Inc represents values of innovation, integrity, and collaboration. With a strong corporate philosophy, the company is dedicated to advancing the field of oncology through the development of novel therapeutics. Oric Pharmaceuticals Inc strives to improve patient outcomes by targeting the root causes of cancer and developing precision medicines. The company's commitment to scientific excellence, ethical conduct, and transparency drives their mission to deliver innovative solutions that address unmet medical needs. Oric Pharmaceuticals Inc embodies a patient-centric approach and fosters collaborations with leading researchers and institutions to accelerate the development of transformative cancer therapies.

In which countries and regions is Oric Pharmaceuticals primarily present?

Oric Pharmaceuticals Inc is primarily present in the United States. With headquarters located in Durham, North Carolina, the company focuses on developing innovative therapies for the treatment of cancer. As a leading pharmaceutical company, Oric Pharmaceuticals Inc has a strong presence in the United States, where it continues to research, market, and distribute its groundbreaking drugs. With a commitment to improving patient outcomes and transforming cancer treatment, Oric Pharmaceuticals Inc plays a vital role in the advancement of healthcare in the United States.

What significant milestones has the company Oric Pharmaceuticals achieved?

Oric Pharmaceuticals Inc has achieved several significant milestones in its history. Notably, the company successfully completed its initial public offering (IPO) in [year], raising [amount] in capital. In addition, Oric Pharmaceuticals Inc has advanced its innovative pipeline, focusing on the development of targeted therapies in the field of oncology. The company has also formed strategic collaborations with leading research institutions and pharmaceutical partners to accelerate drug discovery and development. Moreover, Oric Pharmaceuticals Inc has demonstrated promising results in preclinical and clinical studies, highlighting the potential efficacy of its therapies. These milestones reflect Oric Pharmaceuticals Inc's dedication to revolutionizing cancer treatment and its commitment to driving scientific advancements in the field.

What is the history and background of the company Oric Pharmaceuticals?

Oric Pharmaceuticals Inc is a biopharmaceutical company based in the United States. Established in [year], the company focuses on developing innovative therapies for the treatment of cancer. With a mission to improve patient outcomes by targeting treatment-resistant cancers, Oric Pharmaceuticals has made significant strides in the field of oncology. The company's research and development efforts have resulted in the discovery of promising small molecule inhibitors, which show potential in overcoming resistance mechanisms in tumor cells. Oric Pharmaceuticals Inc has attracted attention from investors and garnered partnerships with renowned organizations, positioning itself as a leader in the fight against cancer.

Who are the main competitors of Oric Pharmaceuticals in the market?

The main competitors of Oric Pharmaceuticals Inc in the market include other pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, and Merck. These companies are also actively involved in the development and commercialization of pharmaceutical products.

In which industries is Oric Pharmaceuticals primarily active?

Oric Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Oric Pharmaceuticals?

The business model of Oric Pharmaceuticals Inc is focused on the development and commercialization of innovative therapies for the treatment of cancer. Oric Pharmaceuticals Inc leverages its expertise in cancer biology and drug discovery to identify and advance potential novel treatments that target specific cancer vulnerabilities. By employing a precision medicine approach, Oric Pharmaceuticals Inc aims to develop therapies that have the potential to improve patient outcomes and address unmet medical needs. With a strong commitment to research and collaboration, Oric Pharmaceuticals Inc strives to make significant advancements in the field of oncology and contribute to the fight against cancer.

What is the P/E ratio of Oric Pharmaceuticals 2025?

The Oric Pharmaceuticals P/E ratio is -2.89.

What is the P/S ratio of Oric Pharmaceuticals 2025?

The Oric Pharmaceuticals P/S ratio is 0.

What is the Quality Investing of Oric Pharmaceuticals?

The Quality Investing for Oric Pharmaceuticals is 2/10.

What is the revenue of Oric Pharmaceuticals 2025?

The revenue cannot currently be calculated for Oric Pharmaceuticals.

How high is the profit of Oric Pharmaceuticals 2025?

The expected Oric Pharmaceuticals profit is -147.63 M USD.

What is the business model of Oric Pharmaceuticals

Oric Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of cancer. The company's business model is based on identifying cancer types caused by specific gene mutations and developing drugs that target these mutations specifically. Oric has developed a proprietary platform technology called "OricOMP" that allows the company to selectively access cancer genes responsible for tumor cell growth. By identifying cancer types triggered by mutated genes, Oric can advance the development of highly specific and effective drugs. Oric's portfolio currently includes two products, Oric-101 and Oric-114, both of which are in clinical development. Oric-101 is an inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B), an enzyme associated with insulin resistance. Oric-114, on the other hand, is an inhibitor of CD73, an enzyme associated with tumor-induced immunosuppression. Oric is also in the early stages of developing other drugs, including inhibitors of other cancer-associated target proteins. Furthermore, Oric's technology can continue to find applications in other disease areas by focusing on other mutated genes. Oric has also formed strategic partnerships with other companies in the industry, including AstraZeneca, to expand its pipeline of cancer drugs. Through these partnerships, Oric can leverage the capabilities and resources of other companies to accelerate the development and commercialization of new drugs. Oric's business model requires significant investment in research and clinical development to ensure its products meet the highest standards of safety and efficacy. The company utilizes its broad network of scientists, academics, and other industry experts to optimize its pipeline of compounds and unlock the potential of OricOMP in new areas of application. Oric aims to market its products globally to achieve maximum penetration in the markets. The company is focused on continuing the clinical development of Oric-101 and Oric-114 while also advancing the commercialization of its already approved drugs. Overall, Oric Pharmaceuticals Inc's business model is centered around the development of highly specific and effective cancer drugs that target cancer genes and mutations. The company will continue to invest in research and clinical development to optimize its pipeline of compounds and solidify its position as a leading company in cancer treatment.

What is the Oric Pharmaceuticals dividend?

Oric Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Oric Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Oric Pharmaceuticals or the company does not pay out a dividend.

What is the Oric Pharmaceuticals ISIN?

The ISIN of Oric Pharmaceuticals is US68622P1093.

What is the Oric Pharmaceuticals WKN?

The WKN of Oric Pharmaceuticals is A2P208.

What is the Oric Pharmaceuticals ticker?

The ticker of Oric Pharmaceuticals is ORIC.

How much dividend does Oric Pharmaceuticals pay?

Over the past 12 months, Oric Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oric Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Oric Pharmaceuticals?

The current dividend yield of Oric Pharmaceuticals is .

When does Oric Pharmaceuticals pay dividends?

Oric Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oric Pharmaceuticals?

Oric Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Oric Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oric Pharmaceuticals located?

Oric Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oric Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oric Pharmaceuticals from 1/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2025.

When did Oric Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/2/2025.

What was the dividend of Oric Pharmaceuticals in the year 2024?

In the year 2024, Oric Pharmaceuticals distributed 0 USD as dividends.

In which currency does Oric Pharmaceuticals pay out the dividend?

The dividends of Oric Pharmaceuticals are distributed in USD.

All fundamentals about Oric Pharmaceuticals

Our stock analysis for Oric Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oric Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.